Wafik S. El-Deiry: Dr. Graham Walker on targeting translesion synthesis to overcome chemotherapy
Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center, shared a post on LinkedIn:
“We heard an enjoyable talk by Dr. Graham Walker from Massachusetts Institute of Technology(MIT) who spoke about his career including 49 years at MIT.
He recounted interesting history going back to when he worked with Bruce Ames (who passed away very recently) to begin his research on mutagenesis mechanisms.
It was interesting to learn that Steve Elledge was his graduate student who cloned umuC.
Dr. Walker spent most of his talk on mechanisms and targeting of translesion synthesis as a strategy to overcome chemotherapy resistance by preventing new mutations.
He also spoke about ROS and antibiotic lethality, controversies around that, and heme in cancer biology.
He gave a great perspective on scientific curiosity and being observant and how he could not have imagined today’s scientific progress when he was starting out.
I found his presentation inspiring for both students and faculty and enjoyed meeting him earlier in the day.”
Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023